Bangalore, India -- (SBWIRE) -- 10/21/2016 -- Regenerative medicine deals with the process of using therapeutically induced or laboratory-grown human tissue to treat damaged or diseased human cells, tissues, or organs. It focuses on repairing, replacing, or regenerating damaged cells, and thus offers a paradigm shift in healthcare treatment. The three main technologies used in regenerative medicine are small molecules and biologics, gene therapy, and cell therapy. Small molecules and biologics help in the regeneration of diseased cells and tissues, whereas cell therapy helps in treating the functioning of existing cells.

Report forecast the regenerative medicine market in Japan to grow at a CAGR of 35.3% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the regenerative medicine market in Japan for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various types of regenerative medicine products to end-users like hospitals, ambulatory surgical centers (ASCs), and clinical research laboratories.

The market is divided into the following segments based on product:
- Tissue Scaffold
- Cell Therapy

Regenerative Medicine Market in Japan 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- CellSeed
- JCR Pharmaceuticals
- Japan Tissue Engineering
- Terumo
- Astellas
- Caladrius Biosciences
- Healios
- Fujifilm
- Rohto Pharmaceuticals

Other prominent vendors
- FUJISOFT Tissue Engineering
- MediBIC
- MEDI NET
- Nikon
- TAKARA
- CMIC
- EPS
- Cyfuse Biomedical
- Irvine Scientific
- Kaken
- Regience
- Sumitomo Dainippon
- Takeda
- Alfresa
- MEDIPAL Holdings
- TOHO

Market driver
- Growing partnerships of MNCs with local vendors in Japan
- For a full, detailed list, view our report

Market challenge
- High cost and failure rate in clinical trials coupled with inadequate clinical evidence
- For a full, detailed list, view our report

Market trend
- Strong pipeline portfolio of regenerative medicines
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 102 pages "Regenerative Medicine Market in Japan 2016-2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Healthcare reforms in Japan, Regulatory landscape in Japan, Reimbursement scenario, Gene therapy: An emerging field in regenerative medicine, Pipeline portfolio, Market landscape, Market segmentation by product, Market segmentation by application, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://www.drugpipeline.net/technavio/regenerative-medicine-market-japan-2016-2020

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.